MDGLMadrigal Pharmaceuticals, Inc.

Filed with the SEC on November 3, 2026 | Form 8-K (Items 2.02, 9.01)

Metric	Q3 FY2026
Revenue	$637.3M
Net Loss	$(73.2M)
Operating Loss	$(240.5M)
EPS (Basic & Diluted)	$(17.33)

---

What Happened

Madrigal Pharmaceuticals filed an 8-K with the SEC on November 3, 2026, disclosing its third-quarter FY2026 financial results. The company reported net revenues of $637.3 million for Q3 FY2026, a striking demonstration of commercial momentum for what is a relatively recent drug launch. Despite robust top-line growth, the company recorded a net loss of $73.2 million and an operating loss of $240.5 million for the quarter, reflecting the heavy investment burden typical of a biopharma in active commercial expansion. Basic and diluted EPS both came in at $(17.33) for the period.

---

Why It Matters

The $637.3 million quarterly revenue figure is the headline number investors will focus on — it signals that Madrigal's commercial infrastructure, built around its NASH/MASH-targeting therapy Rezdiffra, is generating substantial and growing receipts. The gap between revenues and operating income, however, remains wide: a $(240.5M) operating loss against $637.3M in revenue indicates that sales, marketing, R&D, and general expenses are still consuming a significant share of top-line gains. The net loss of $(73.2M) — considerably narrower than the operating loss — suggests meaningful non-operating income or adjustments at work, a detail investors will want to dissect in the full financial statements accompanying this filing.

For context, the company reported $0 in revenues as recently as Q1 FY2025, making this quarter's $637.3M figure a transformative milestone in just over a year of commercial activity. The stock is up 8.78% on the day to $469.03, reflecting market enthusiasm for the revenue trajectory.

---

Analysis

The Q3 FY2026 print tells a story of a company transitioning rapidly from pre-commercial to commercially scaled — and doing so at a pace that has clearly exceeded earlier consensus expectations, given today's sharp share-price reaction. The persistence of a large operating loss is not necessarily alarming at this stage: biopharma companies launching into major therapeutic categories routinely front-load spending on market access, physician education, and pipeline development. What matters structurally is whether the revenue ramp is steep enough to close the operating gap within a credible timeframe.

The notable divergence between the operating loss ($(240.5M)) and the net loss ($(73.2M)) — a gap of roughly $167M — warrants close scrutiny when the full income statement becomes available. Non-operating items of that magnitude could reflect investment income on a substantial cash position, fair-value adjustments, or other one-time items; understanding their sustainability will be important for modeling forward earnings power.

Looking ahead, the key question is whether Q3's revenue level represents a durable run-rate or whether it includes timing benefits (such as inventory stocking). Investors and analysts will be watching next quarter's figures closely for confirmation of a sustained $600M+ quarterly revenue cadence. This filing coincides with StockWatch's initiation of coverage on MDGL today — readers can access that full analysis for a deeper fundamental perspective.

---

Disclaimer

This report is prepared for informational purposes only and does not constitute investment advice, a solicitation to buy or sell any security, or a recommendation of any kind. All financial figures cited are sourced exclusively from the company's official SEC filing XBRL data as described above. Past performance is not indicative of future results. Investors should conduct their own due diligence and consult a qualified financial adviser before making any investment decision.

Existing Coverage

StockWatch has full coverage on MDGL, published 2026-11-03. Read our Initiating Coverage →

Source

Filed with the SEC on 2026-11-03. Read the original filing on EDGAR: https://www.sec.gov/Archives/edgar/data/1157601/000162828026069093/mdgl-20261103.htm